Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

FT576

Cell therapy (Stem-cell derived) · Kills target cells, directed at B-cell maturation antigen (BCMA) (TNFRSF17) · developed by Fate Therapeutics

Phase 1 Most advanced trial (none active)
FATE Developer
1 Registered trials

What is FT576?

FT576 is an allogeneic natural killer cell therapy derived from a clonal, CD38-knockout induced pluripotent stem cell line. The cells express a anti-BCMA chimeric antigen receptor, a high-affinity non-cleavable CD16 and an IL-15/IL-15 receptor fusion protein. It is being studied in multiple myeloma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (Stem-cell derived)
Targets
B-cell maturation antigen (BCMA) (TNFRSF17) (antigen)
Mechanism
Kills target cells, directed at B-cell maturation antigen (BCMA) (TNFRSF17)
Therapy area
Oncology
Developer
Fate Therapeutics (FATE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05182073 Phase 1 Multiple Myeloma Completed FATE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Multiple MyelomaMyeloma

Other drugs acting on TNFRSF17

More from Fate Therapeutics

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the FATE page.

Follow FATE, the company behind FT576

See FATE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

FATE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.